Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

How to prevent corneal haze in surface ablation techniques

Poster Details

First Author: S.Lozano Ruiz SPAIN

Co Author(s):    C. Gomez Cabrera   M. Rodriguez Calvo de Mora                 

Abstract Details

Purpose:

Corneal haze is a complication of refractive surgery, produced by the superficial cicatrisation of the stroma, in which the symptoms are blurred vision with diminished visual acuity. Therefore, it is paramount to prevent it.

Setting:

Refractive and cornea department. Private hospital .

Methods:

Woman, operated refractive surgery a year ago, with no medical record of interest except for having taken oral contraceptives. Her visual acuity (Va) without distance correction was 0.4 on the right eye (OR), improving to 1.2 with a subjective graduation of -1.75 and 0.2 on the left eye (OI), improving to 1 -1.5-0.5 to 145 �Â�°. Biomicroscopy, intraocular pressure and funduscopy within the standard parameters. The applied treatment was -1.75 OR and -1.5 -0.5 to 140 �Â�º OS. In the annual review, the patient continues with VA of 1 in both eyes and there aren,t signs of corneal haze.

Results:

In order to prevent corneal haze, the most widespread variant is the use of intraoperative mitomycin C (MMC). In our center we apply MMC at 0.02 on the ablated stroma for 15 seconds. After surgery we prescribe non-steroidal, anti-inflammatory eye drops for three days and antibiotic eye drops associated with steroids until the end of the month.

Conclusions:

Corneal haze is a complication with an impact on vision and, therefore, its prevention is fundamental. Currently, the use of intraoperative mitomycin C together with the association of a post-operative combination of non-steroidal, anti-inflammatory drugs in its adequate dosage with the use of steroids may be good preventive options for this frequent complication in surgeries of superficial ablation.

Financial Disclosure:

NONE

Back to Poster listing